CDKN2A and astrocytoma (excluding glioblastoma): Specific drivers of sporadic high-grade astrocytomas have been elucidated in the past years through genome-wide sequencing [3], and similar techniques have been applied to study NF1-associated astrocytomas, identifying genetic alterations in TP53, CDKN2A, and ATRX [4].